Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Net Cash Flow: 2010-2025

Historic Net Cash Flow for Ironwood Pharmaceuticals (IRWD) over the last 15 years, with Sep 2025 value amounting to $47.6 million.

  • Ironwood Pharmaceuticals' Net Cash Flow rose 375.24% to $47.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.9 million, marking a year-over-year increase of 328.34%. This contributed to the annual value of -$3.6 million for FY2024, which is 99.37% up from last year.
  • As of Q3 2025, Ironwood Pharmaceuticals' Net Cash Flow stood at $47.6 million, which was up 417.59% from -$15.0 million recorded in Q2 2025.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Cash Flow peaked at $84.1 million during Q1 2023, and registered a low of -$565.5 million during Q2 2023.
  • In the last 3 years, Ironwood Pharmaceuticals' Net Cash Flow had a median value of -$15.0 million in 2025 and averaged -$47.0 million.
  • Examining YoY changes over the last 5 years, Ironwood Pharmaceuticals' Net Cash Flow showed a top increase of 414.44% in 2023 and a maximum decrease of 535.30% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Net Cash Flow (Quarterly) stood at $45.9 million in 2021, then soared by 78.87% to $82.0 million in 2022, then tumbled by 123.48% to -$19.3 million in 2023, then spiked by 101.70% to $327,000 in 2024, then soared by 375.24% to $47.6 million in 2025.
  • Its Net Cash Flow was $47.6 million in Q3 2025, compared to -$15.0 million in Q2 2025 and $19.9 million in Q1 2025.